摘要
目的 评价小剂量重组组织型纤溶酶原激活物 (r-TPA)与国产重组链激酶 (r-SK)治疗急性心肌梗死 (AMI)的疗效 ,并比较二者的差异。方法 71例AMI患者 ,均采用静脉溶栓 ,随机分为r -TPA治疗组 (36例 )和r-SK治疗组 (35例 )。结果 梗死相关血管再通率r-TPA组为 77 78% (2 8/ 36 ) ,r-SK组为 74 2 9% (2 6 / 35 ) ,P >0 0 5 ,差异不显著 ;4周病死率r-TPA组为 5 5 6 % (2 / 36 ) ,r-SK组为 5 71(2 / 35 ) % ,差异不显著 (P >0 0 5 ) ;两组均未出现严重出血。但r-SK组过敏反应发生率为 8 5 7% (3/ 35 ) ,低血压发生率为 2 86 % (1/ 35 )。结论 加速法使用国产r -SK治疗AMI,梗死相关血管再通率、4周病死率r-TPA与r-SK相似 ,但过敏反应及低血压发生率r-SK较r-TPA高 ,国产r-SK治疗AMI安全有效 ,无严重出血 ,费用较r-TPA低 ,值得临床推广使用。
Objective To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator(r-TPA) and recombinant strepokinase(r-SK) in patients with acute myocardial infarction (AMI). Methods 71 patients were divided into r-TPA group (36 cases) and r-SK group (35 cases). Results The reperfusion rates of infarct-related arteries in r-TPA and r-SK groups were 77.78%(28/36) and 74.29%(26/35), P >0.05. The total 4-week mortality in r-TPA and r-SK groups were 5.56%(2/36) and 5.71%(2/35), P >0.05. Two groups had no severe bleeding. Conclusion The r-SK is effective, reliable and safe thrombolytic agents for AMI.
出处
《中国急救医学》
CAS
CSCD
北大核心
2001年第11期633-634,共2页
Chinese Journal of Critical Care Medicine
基金
全军"九五"重点课题分题 (No .96Z0 5 2 )
关键词
纤溶酶原激活物
重组链激酶
血栓溶解疗法
心肌梗死
AMI
Recombinant tissue type plasminogen activator(r-TPA)
Recombinant strepokinase(r-SK)
Thrombolytic
Acute myocardial infarction(AMI)